Home
Halozyme Therapeutics HALO paid Forbes-Tate $80K for lobbying in Q2 2026 · Medicare, Health Issues
Trade details
- Type
- Lobbying report
- Amount
- $80,000
- Quarter
- Q2 2026
- Client
- Halozyme Therapeutics
- Reported
- 26/07/20
Up 14.3% from last quarter
What else happened in Halozyme Therapeutics around then
Filed or reported within 30 days of the trade day · 05/31~07/30Halozyme Therapeutics's other lobbying reports
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$70K
$70K
Reported 04/18
for Q1
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$60K
$60K
Reported 01/18
for Q4 2025
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$60K
$60K
Reported 25/10/18
for Q3 2025
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$60K
$60K
Reported 25/07/18
for Q2 2025
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$60K
$60K
Reported 25/04/15
for Q1 2025